<DOC>
	<DOCNO>NCT01615250</DOCNO>
	<brief_summary>This randomize study efficiency safety intramyocardial implantation peripheral mononuclear cell high concentration CD34+ stem cell patient myocardial ischemia preparatory course shock - wave therapy .</brief_summary>
	<brief_title>Implantation Peripheral Stem Cells Patient With Ischemic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients ischemic cardiomyopaty HF IIIV NYHA class MI 6 month study LVEF le 35 % Absence effect coronary revascularization 6 month Optimal pharmacological therapy le 8 week Heart transplantation contraindicate Patients implantable cardioverterdefibrillator ( ICD ) cardiac resynchronization therapy defibrillator ( CRTD ) Patients give informed consent Acute coronary syndrome Coronary revascularization le 6 month Patients require surgical correction postMI aneurism LV wall thickness le 5 mm site possible injection Patients CRT implant within 3 month cell injection Clinically significant associate disease Active oncology desiase Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>